Compare RNAZ & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNAZ | CLPS |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 28.3M |
| IPO Year | 2021 | 2017 |
| Metric | RNAZ | CLPS |
|---|---|---|
| Price | $1.40 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 17.7K | 12.8K |
| Earning Date | 08-14-2026 | 10-16-2026 |
| Dividend Yield | N/A | ★ 12.87% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $0.80 |
| 52 Week High | $12.60 | $1.24 |
| Indicator | RNAZ | CLPS |
|---|---|---|
| Relative Strength Index (RSI) | 31.10 | 45.68 |
| Support Level | N/A | $0.86 |
| Resistance Level | $1.93 | $0.99 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 0.00 | 47.11 |
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
CLPS Inc is information technology, consulting and solutions service provider, focused on delivering services mainly to world-wide institutions, including banking, wealth management, ecommerce, and automotive areas both in China and globally. It has been at the forefront of driving digital transformation and optimizing operational efficiency across industries through innovations in artificial intelligence (AI), cloud computing, and data. It diverse business lines span sectors including fintech, payment and credit services, e-commerce, education and study abroad programs, and world-wide tourism integrated with transportation services. Its segments are IT services and academic education service. Majority of revenue comes from IT services segment. Its products are NiBot RPA, and CAKU.